GROWTH-INHIBITORY EFFECT OF QUERCETIN AND PRESENCE OF TYPE-II ESTROGEN-BINDING SITES IN HUMAN COLON-CANCER CELL-LINES AND PRIMARY COLORECTAL TUMORS

被引:151
作者
RANELLETTI, FO
RICCI, R
LAROCCA, LM
MAGGIANO, N
CAPELLI, A
SCAMBIA, G
BENEDETTIPANICI, P
MANCUSO, S
RUMI, C
PIANTELLI, M
机构
[1] UNIV CATTOLICA SACRO CUORE, DEPT PATHOL, I-00168 ROME, ITALY
[2] UNIV CATTOLICA SACRO CUORE, DEPT GYNECOL, I-00168 ROME, ITALY
[3] UNIV CATTOLICA SACRO CUORE, DEPT HEMATOL, I-00168 ROME, ITALY
关键词
D O I
10.1002/ijc.2910500326
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
We studied the effect of quercetin (Q) on the proliferation of HT-29, WiDr, COLO 201, and LS-174T human colon cancer cell lines. Q, between 10 nM and 10-mu-M, exerted a dose-dependent, reversible inhibition of cell proliferation. Cell-cycle analysis revealed that the growth-inhibitory effect of Q was due to a blocking action in the G0/G1 phase. Using a whole-cell assay with 17-beta-[H-3]-estradiol as tracer, we demonstrated that all these cell lines contain type-II estrogen-binding sites (type-II EBS). By using Q and other chemically related flavonols (3,7-4'-trimethoxyquercetin, 3,7,3',4'-tetramethoxyquercetin, kaempferol, morin, and rutin), we observed that the affinities of these compounds for type-II EBS are correlated with their growth-inhibitory potential. Furthermore, the Q sensitivity of the colon cancer cell lines was correlated with the number of type-II EBS/cell. Then Q could regulate colon cancer cell growth through a binding interaction with type-II EBS. This mechanism could also be active in vivo as we have observed that cytosolic type-II EBS are present in primary colorectal cancers and that Q is effective in inhibiting the in vitro bromodeoxyuridine incorporated by neoplastic cells in these cancers.
引用
收藏
页码:486 / 492
页数:7
相关论文
共 29 条
[1]
ADLERCREUTZ H, 1984, GASTROENTEROLOGY, V86, P761
[2]
HIGH AEROBIC GLYCOLYSIS OF RAT HEPATOMA-CELLS IN CULTURE - ROLE OF MITOCHONDRIAL HEXOKINASE - (L-LACTIC ACID-D-GLUCOSE-D-GALACTOSE-LIVER-NEOPLASIA) [J].
BUSTAMANTE, E ;
PEDERSEN, PL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1977, 74 (09) :3735-3739
[3]
CLARK JH, 1978, J BIOL CHEM, V253, P7630
[4]
GABOR M, 1988, BIOCH CELLULAR MED P, V280, P1
[5]
GRAHAM S, 1978, JNCI-J NATL CANCER I, V61, P709
[6]
THE EFFECT OF QUERCETIN ON THE PHOSPHORYLATION ACTIVITY OF THE ROUS-SARCOMA VIRUS TRANSFORMING GENE-PRODUCT INVITRO AND INVIVO [J].
GRAZIANI, Y ;
ERIKSON, E ;
ERIKSON, RL .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1983, 135 (03) :583-589
[7]
DISPOSITION OF QUERCETIN IN MAN AFTER SINGLE ORAL AND INTRAVENOUS DOSES [J].
GUGLER, R ;
LESCHIK, M ;
DENGLER, HJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1975, 9 (2-3) :229-234
[8]
HAENSZEL W, 1980, JNCI-J NATL CANCER I, V64, P17
[9]
INHIBITORY EFFECT OF QUERCETIN ON THE SYNTHESIS OF A POSSIBLY CELL-CYCLE-RELATED 17-KDA PROTEIN, IN HUMAN COLON CANCER-CELLS [J].
HOSOKAWA, N ;
HOSOKAWA, Y ;
SAKAI, T ;
YOSHIDA, M ;
MARUI, N ;
NISHINO, H ;
KAWAI, K ;
AOIKE, A .
INTERNATIONAL JOURNAL OF CANCER, 1990, 45 (06) :1119-1124
[10]
KHOCKBIN S, 1988, CYTOMETRY, V9, P699